Atrium Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
Atrium Therapeutics Inc RNA
$8.29
▲ +1.22%
(+$0.10)
🔥 High Short Interest
Open
$8.20
Prev Close
$8.19
Day Range
$8.10 – $8.37
52W Range
$8.16 – $73.06
Market Cap
$141.81M
Beta
1.18
EPS (TTM)
$-5.04
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2026-02-27 |
| Shares Out. | 17,110,000 |
| Phone | 13026587581 |
| Employees | 391 |
| Website | aviditybiosciences.com ↗ |
| Revenue | $3.0M |
| Gross Profit | $3.0M |
| Net Income | -$20.2M |
| Total Assets | $280.5M |
| Total Liabilities | $65.9M |
| Equity | $214.6M |
About Atrium Therapeutics Inc
Atrium Therapeutics Inc is a biopharmaceutical firm focused on developing RNA-based therapeutics for cardiac conditions, including cardiomyopathies. Its platform technology is designed to enable targeted delivery of RNA therapeutics to heart tissue by combining ligand-based targeting approaches with oligonucleotide-based therapies. The company's development pipeline includes programs targeting genetically associated forms of cardiomyopathy, specifically involving the PRKAG2 and PLN genes.
Atrium Therapeutics Inc is a publicly traded company under the ticker symbol RNA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
8 analysts (2026-09-01)